VT7208 / Processa Pharmaceuticals - LARVOL DELTA

Processa Pharmaceuticals…announced it has acquired Vidya Therapeutics…developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis (GlobeNewswire) - "Concurrent with the acquisition, Processa entered into a definitive agreement for a private placement financing expected to result in gross proceeds of approximately $200 million, before deducting placement agent and other offering expenses, from a syndicate of new and existing investors....Processa expects to use the proceeds to support the advancement of VT-7208 through multiple clinical milestones, including data from a Phase 2 proof-of-concept study in food allergy anticipated in the second half of 2027, data from a Phase 2 proof-of-concept study in CSU anticipated in the first half of 2028, and data from a Phase 2 proof-of-concept study in RMS anticipated in the second half of 2028. The company's cash and cash equivalents at closing...are expected to fund operations into the second half of 2029."

Financing • M&A • P2 data • Chronic Spontaneous Urticaria • Food Hypersensitivity • Multiple Sclerosis

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Vidya Therapeutics Inc | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Vidya Therapeutics Inc

New P1/2 trial • CNS Disorders • Multiple Sclerosis